Trial Profile
Pilot Study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Irinotecan
- Indications Liver cancer
- Focus Adverse reactions
- 16 May 2016 New trial record